Major equity ownership of Corcept Therapeutics is heavily concentrated among prominent institutional asset management firms, large mutual fund providers, and specialized healthcare investment funds. Prominent institutional heavyweights such as BlackRock, Vanguard Group, and specialized biotech funds hold substantial aggregate blocks of common stock, influencing corporate governance alongside executive management.